Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 double-blind study of dersimelagon (MT-7117) in erythropoietic protoporphyria or X-linked protoporphyria
jRCT2080225355Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma Corporation
- Start
- Aug 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of dersimelagon in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) (3 arms), sponsored by Mitsubishi Tanabe Pharma Corporation. Primary endpoint: Change from baseline in average daily sunlight exposure time to first prodromal symptom at Week 26. Started Aug 2020; status: completed.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on jRCT2080225355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225355.